Kaneva 150 mg (Tablet)
Unit Price: ৳ 1,000.00 (3 x 10: ৳ 30,000.00)
Strip Price: ৳ 10,000.00
Medicine Details
| Category | Details |
|---|---|
| Generic | Erlotinib |
| Company | Beximco pharmaceuticals ltd |
| Also available as |
Indications
- First-line treatment of patients with metastatic Non-Small Cell Lung cancer (NSCLC)
- Maintenance treatment of patients with locally advanced or metastatic NSCLC
- Treatment of locally advanced or metastatic NSCLC after failure of at least one prior chemotherapy regimen
- First-line treatment of patients with locally advanced, unresectable or metastatic pancreatic cancer
Description
- Quinazolinamine chemical composition
- Reversibly inhibits the kinase activity of EGFR
- Binds with higher affinity to EGFR exon 19 deletion or exon 21 (L858R) mutations
- Inhibition of other tyrosine kinase receptors not fully characterized
Dosage & Administration
- Recommended daily dose of Erlotinib for NSCLC is 150 mg taken on an empty stomach
- Recommended daily dose of Erlotinib for pancreatic cancer is 100 mg taken once daily in combination with gemcitabine
- Dose reduction and increment under specific conditions
- Special dosing considerations for concurrent cigarette smoking
Interaction
- Interaction with coumarin-derived anticoagulants, including warfarin
- Metabolized predominantly by CYP3A4
- Pre-treatment with the CYP3A4 inducer Rifampicin
- Co-administration of Kaneva with drugs affecting gastric pH
Side Effects
- Common adverse reactions such as rash, diarrhea, anorexia, fatigue, dyspnea, cough, nausea, and vomiting
- Serious adverse reactions including Interstitial Lung Disease (ILD), Renal Failure, and Hepatotoxicity
Pregnancy & Lactation
- Pregnancy category D
- Potential for serious adverse reactions in nursing infants
- Consideration for discontinuation of nursing or drug
Precautions & Warnings
- Occurrence and management of Interstitial Lung Disease (ILD)
- Monitoring for renal function and electrolytes
- Periodic liver testing and monitoring hepatic impairment
- Discontinuation of Kaneva for specific conditions
Use in Special Populations
- Safety and effectiveness in pediatric patients not established
- No significant differences in safety or efficacy observed between elderly and younger subjects
Overdose Effects
- Tolerance of single and weekly doses up to a certain level
- Unacceptable incidence of severe adverse reactions above the recommended dose
- Management of suspected overdose
Therapeutic Class
- Targeted Cancer Therapy
Storage Conditions
- Store at a temperature not exceeding 30°C
- Store in a dry place
- Protection from light and moisture